One in Seven Semaglutide Patients Skipped the Label's 0.25 mg Start, and More of Them Quit Early

The labels for both injectable semaglutide products start patients on 0.25 mg once a week. The Ozempic label says to "start at 0.25 mg," and the Wegovy label holds that dose for four weeks before any step up. A claims study published October 19 in Diabetes, Obesity and Metabolism found that 14.5 percent of US adults were started at 1.0 mg a week or higher instead.

What the study measured

The authors (Belalcazar, Gao, Modi, Meer and Kuo) used MarketScan insurance claims from 2018 to 2021. They counted adults with diabetes, obesity or both who had never taken an incretin drug before and then started injectable semaglutide. Each person was followed for 12 months.

The team split starting doses into low (0.5 mg a week or less) and high (1.0 mg or more) and labeled the high group an off-label regimen. Of the 48,658 adults, 14.5 percent landed in the high group. That is roughly 7,000 people, a figure Trestlewire calculated from the published percentage.

Those 7,000 people were more likely to stop early. The study reports a hazard ratio of 1.25, meaning a 25 percent higher risk of early discontinuation, after adjusting for age, obesity status, other illnesses and cost. One-year persistence on the drug was also lower in the high-dose group (p = 0.01). The authors call high-dose initiation "a modifiable risk factor," which is their reading, not a finding the data can prove.

How far the high starters skipped

The Ozempic label lays out a ladder. Start at 0.25 mg, move to 0.5 mg after four weeks, and go to 1 mg only after at least four weeks on 0.5 mg. A patient who begins at 1 mg jumps past at least eight weeks of that schedule on day one.

The study does not say why prescribers did it. Claims data record a pharmacy fill, not a conversation. A doctor may have judged a patient ready for more, or may have been working from a different supply or habit. The abstract does not say which.

Who got the higher dose

The odds of a high starting dose were higher in the West and South, among endocrinologists (p = 0.02), and for men, younger adults and patients with obesity rather than overweight. They were also higher for starts in 2018 than in 2019 through 2021. That last result points to the practice fading over the study window, though the data stop in 2021 and cannot say how common it is today.

What the evidence cannot show

This is one retrospective study. Adjustment for age, obesity status, comorbidity and cost does not remove every difference between patients who got a high dose and those who did not. A person a prescriber expected to tolerate more may differ from other patients in ways claims never record.

The abstract does not report why patients stopped, so the link to side effects is untested here. It also does not give the length of the "early" window in the text available to this reporter. The full paper sits behind a publisher page that blocks automated access, so this report rests on the published abstract and the two drug labels, not the full methods section. The result has not been replicated.

Anyone with questions about a prescribed dose is the person to ask a prescriber or pharmacist. This article is not medical advice.